Cannara Biotech Inc.
LOVE.TO
TSX
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | 81.39M | 79.97M | 76.57M | 72.88M | 67.78M |
| Total Other Revenue | 272.00K | 272.00K | 332.10K | 151.80K | 203.00K |
| Total Revenue | 81.66M | 80.24M | 76.90M | 73.04M | 67.93M |
| Cost of Revenue | 46.96M | 45.80M | 43.08M | 40.51M | 39.47M |
| Gross Profit | 34.70M | 34.45M | 33.82M | 32.52M | 28.46M |
| SG&A Expenses | 19.95M | 18.31M | 16.61M | 15.69M | 15.19M |
| Depreciation & Amortization | 1.10M | 1.11M | 1.13M | 925.20K | 942.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.78M | 65.81M | 61.33M | 57.68M | 56.28M |
| Operating Income | 12.88M | 14.43M | 15.57M | 15.36M | 11.65M |
| Income Before Tax | 10.96M | 12.20M | 12.94M | 12.40M | 9.77M |
| Income Tax Expenses | 3.63M | 3.77M | 3.59M | 1.26M | 90.60K |
| Earnings from Continuing Operations | 7.33 | 8.42 | 9.35 | 11.14 | 9.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.33M | 8.42M | 9.35M | 11.14M | 9.68M |
| EBIT | 12.88M | 14.43M | 15.57M | 15.36M | 11.65M |
| EBITDA | 17.30M | 19.03M | 20.17M | 19.62M | 16.13M |
| EPS Basic | 0.08 | 0.09 | 0.10 | 0.12 | 0.11 |
| Normalized Basic EPS | 0.07 | 0.08 | 0.09 | 0.08 | 0.06 |
| EPS Diluted | 0.07 | 0.08 | 0.09 | 0.12 | 0.10 |
| Normalized Diluted EPS | 0.07 | 0.08 | 0.08 | 0.08 | 0.05 |
| Average Basic Shares Outstanding | 372.95M | 367.15M | 363.45M | 362.03M | 360.62M |
| Average Diluted Shares Outstanding | 380.59M | 374.42M | 369.82M | 367.96M | 366.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |